Literature DB >> 6617681

Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome.

H Neuss, J Buss, M Schlepper, R Berthold, V Mitrović, A Krämer, W J Musial.   

Abstract

The effect of flecainide in 12 patients with the Wolff-Parkinson-White syndrome was analyzed with respect to the anterograde and retrograde conduction properties of the accessory pathway, the modes of initiation and termination of circus movement tachycardias, and the ventricular response during induced atrial fibrillation. The principal effect of this drug was to depress both anterograde and retrograde conduction of the accessory pathway. In 8/9 cases circus movement tachycardia was terminated by prolongation of the retrograde effective refractory period of the accessory pathway. Flecainide increased the shortest and the mean cycle length during induced atrial fibrillation. It is concluded that the drug may be of potential benefit in patients with paroxysmal supraventricular tachycardias in patients with the Wolff-Parkinson-White syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617681     DOI: 10.1093/oxfordjournals.eurheartj.a061472

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

Review 1.  Which patient should be referred to an electrophysiologist: supraventricular tachycardia.

Authors:  Richard J Schilling
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

2.  Propafenone in Wolff-Parkinson-White syndrome at risk.

Authors:  V Santinelli; P Turco; M De Paola; D Smimmo; M Giasi; C Santinelli; M Chiariello; M Condorelli
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

3.  Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia.

Authors:  A Fujiki; M Tani; S Yoshida; H Inoue
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

4.  Flecainide plasma concentrations correlated to inhibition of a bundle of Kent.

Authors:  E Casiglia; C Martines; R Moretto; D Piovan
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

5.  Electrophysiological effects of the combination of mexiletine and flecainide in guinea-pig ventricular fibres.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

6.  Effect of intravenous flecainide on atrial vulnerability in man.

Authors:  T Pop; N Treese
Journal:  Drugs       Date:  1985       Impact factor: 9.546

7.  Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.

Authors:  A J Camm; K J Hellestrand; A W Nathan; R S Bexton
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 8.  Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  B Holmes; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

9.  Flecainide-induced incessant orthodromic atrioventricular reentrant tachycardia in Wolff-Parkinson-White syndrome: Uneven depression of accessory pathway conduction.

Authors:  Oscar A Pellizzón; Manlio F Márquez; Mario D González; Sebastián Nannini; Rodolfo Leiva; Antonia Catalano; Pedro Iturralde
Journal:  HeartRhythm Case Rep       Date:  2016-08-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.